The innovative medicines initiative: a European response to the innovation challenge.
The Innovative Medicines Initiative (IMI) was launched in 2008 as a large-scale public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). With a total budget of €2 billion, the IMI aims to boost the development of new medicines across Europe by implementing new collaborative endeavors between large pharmaceutical companies and other key actors in the health-care ecosystem, i.e., academic institutions, small and medium enterprises, patients, and regulatory authorities. Projects conducted by IMI consortia have already delivered meaningful results, providing proof-of-concept evidence for the efficiency of this new model of collaboration. In this article we review recent achievements of the IMI consortia and discuss the growing interest in the IMI as a best-practice model to reinvigorate drug development.
Innovative Medicines Initiative, Brussels, Belgium. michel.goldman@imi.europa.eu
M
M
Goldman
D003299:Cooperative Behavior; D055808:Drug Discovery / Q000191:economics / Q000458:organization & administration*; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D004335:Drug and Narcotic Control / Q000191:economics / Q000458:organization & administration*; D005062:European Union; D006077:Government Agencies / Q000191:economics / Q000458:organization & administration*; D006801:Humans; D009936:Organizational Innovation / Q000191:economics; D017149:Private Sector / Q000191:economics / Q000458:organization & administration*; D055818:Public-Private Sector Partnerships / Q000191:economics / Q000458:organization & administration*